Browse studies
Find your next paid study
2 recruiting studies matching your filters
Phase 2
Olomorasib Plus Pembrolizumab as First-Line Treatment for KRAS G12C Mutant, PD-L1 TPS 1-49% Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
This clinical trial evaluates the combination of olomorasib and pembrolizumab as a first-line treatment for patients with advanced or metastatic non-small cell…
Lung CancerLung Cancer (NSCLC)Locally Advanced NSCLC+1 more
Estimated
~$10 – $6,250
UNC Lineberger Comprehensive Cancer CenterNCT07639242
Phase 2
A Multi-center Phase II Study of Combining Cabozantinib and Atezolizumab as the 1st Line Therapy for PD-L1 Negative Advanced/Metastatic NSCLC (Cabatezo-1)
NSCLC patients with low expression level of PD-L1, esp. those with its level less than 1%, do not derive much benefit from anti-PD-1/L1 therapy (e.g. atezoilzu…
Lung CancerNSCLC Stage IVMetastatic NSCLC - Non-Small Cell Lung Cancer+1 more
Estimated
~$10 – $7,500
Jun Zhang, MD, PhDNCT05859217